BPXA.F Stock Analysis
BP
Uncovered
Bellicum Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2014-12-18. The firm has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). The company uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.